wegovy semaglutide injection 0.25 mg 0.25mg FlexTouch Solution for behavior change WEGOVY 0.25 MG FLEXTOUCH (

According to the labeling, semaglutide is contraindicated (meaning not suitable) for people with: A personal or family history of medullary thyroid carcinoma: 25% of medullary thyroid carcinoma cancer cases run in families, and the condition appears to have a genetic component

It works through several mechanisms: Enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppresses glucagon release , reducing hepatic glucose production Slows gastric emptying , which prolongs satiety and reduces appetite Acts on brain appetite centers to decrease food intake and promote weight loss Semaglutide is administered as a once-weekly subcutaneous injection (Ozempic, Wegovy) or as a daily oral tablet (Rybelsus)

perhaps its a combination

The highest risk would be if you were injecting the substance

We also appreciate the technical support of Simona Ferjan, M.D., Ph.D